Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

467

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

DRUG: sacubitril/valsartan
DRUG: valsartan
DRUG: sacubitril/valsartan matching placebo
DRUG: valsartan matching placebo

Sponsor

Novartis Pharmaceuticals